Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dong-A Socio Holdings

http://en.donga.co.kr/

Latest From Dong-A Socio Holdings

New Deals, Modalities In Sights In Japan After Relatively Quiet 2022

After a comparatively subdued 2022 in terms of M&A and other deal-making, a strengthening currency and interest in new areas such as digital tools and cell and gene therapy might see a rebound in activity this year, which should also see domestic approvals of several potential blockbusters and more support for bioventures.

Japan Business Strategies

Dong-A ST Achieves Therapeutic Equivalence With Stelara Biosimilar

Dong-A has achieved therapeutic equivalence for its ustekinumab biosimilar candidate DMB-3115 in clinical studies and now plans to file for marketing authorization for the product in both the EU and US.

Clinical Trials Advertising, Marketing & Sales

New Deals, Modalities In Sights In Japan After Relatively Quiet 2022

After a comparatively subdued 2022 in terms of M&A and other deal-making, a strengthening currency and interest in new areas such as digital tools and cell and gene therapy might see a rebound in activity this year, which should also see domestic approvals of several potential blockbusters and more support for bioventures. 

Japan Scrip Perspectives

Moderna Expands mRNA Capability Through $85m OriCiro Acquisition

Moderna has made its first-ever acquisition with the $85m purchase of OriCiro Genomics, a Japanese bioventure with DNA synthesis and amplification technology. The deal is expected to contribute to Moderna’s capabilities in both manufacturing and R&D.

M & A Commercial
See All

Company Information

  • Industry
  • Distributors
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • OTC, Consumer
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Dong-A Pharmaceutical Co., Ltd (Dong-A Pharm)
    • Dong-A Science Technology Co., Ltd (Dong-A ST)
    • Dong-A Socio Group
    • JCOM Co. Ltd.
    • Mezzion Co. Ltd.
UsernamePublicRestriction

Register